Beta-lactam combination therapy for the treatment of Staphylococcus aureus and Enterococcus species bacteremia: A summary and appraisal of the evidence

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Staphylococcal bacteremia and enterococcal bacteremia are prevalent in hospitalized or recently instrumented patients, and are associated with significant morbidity and mortality. They are often difficult to treat due to the pathogenicity of the organisms, poor response to antibiotics, and increasing development of multidrug resistance. Therefore, there has been increasing interest in combination therapy for the treatment of these infections. The aim of this review was to summarize and assess the evidence supporting combination beta-lactam therapy for both Staphylococcus aureus and Enterococcus species blood stream infections. Currently, there is promising in vitro data but little clinical evidence supporting combination beta-lactam therapy for this indication. Further clinical investigations are needed to elucidate the potential benefits of beta-lactam combination therapy over monotherapy for Gram-positive bacteremia, although combination therapy may be useful in refractory cases of bacteremia that do not respond to standard antibiotic therapy.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalInternational Journal of Infectious Diseases
Volume63
DOIs
StatePublished - Oct 2017

Keywords

  • Beta-lactam antibiotic therapy
  • Combination antibiotic therapy
  • Enterococcus species
  • Methicillin-resistant Staphylococcus aureus
  • Staphylococcus aureus
  • Vancomycin-resistant Enterococcus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Beta-lactam combination therapy for the treatment of Staphylococcus aureus and Enterococcus species bacteremia: A summary and appraisal of the evidence'. Together they form a unique fingerprint.

  • Cite this